These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 32139119)
1. Moyamoya disease patient mutations in the RING domain of RNF213 reduce its ubiquitin ligase activity and enhance NFκB activation and apoptosis in an AAA+ domain-dependent manner. Takeda M; Tezuka T; Kim M; Choi J; Oichi Y; Kobayashi H; Harada KH; Mizushima T; Taketani S; Koizumi A; Youssefian S Biochem Biophys Res Commun; 2020 May; 525(3):668-674. PubMed ID: 32139119 [TBL] [Abstract][Full Text] [Related]
2. Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism. Ahel J; Lehner A; Vogel A; Schleiffer A; Meinhart A; Haselbach D; Clausen T Elife; 2020 Jun; 9():. PubMed ID: 32573437 [TBL] [Abstract][Full Text] [Related]
4. A new horizon of moyamoya disease and associated health risks explored through RNF213. Koizumi A; Kobayashi H; Hitomi T; Harada KH; Habu T; Youssefian S Environ Health Prev Med; 2016 Mar; 21(2):55-70. PubMed ID: 26662949 [TBL] [Abstract][Full Text] [Related]
5. UBC13 is an RNF213-associated E2 ubiquitin-conjugating enzyme, and Lysine 63-linked ubiquitination by the RNF213-UBC13 axis is responsible for angiogenic activity. Habu T; Harada KH FASEB Bioadv; 2021 Apr; 3(4):243-258. PubMed ID: 33842849 [TBL] [Abstract][Full Text] [Related]
6. Moyamoya disease-associated protein mysterin/RNF213 is a novel AAA+ ATPase, which dynamically changes its oligomeric state. Morito D; Nishikawa K; Hoseki J; Kitamura A; Kotani Y; Kiso K; Kinjo M; Fujiyoshi Y; Nagata K Sci Rep; 2014 Mar; 4():4442. PubMed ID: 24658080 [TBL] [Abstract][Full Text] [Related]
7. Genetic analysis of Tashiro R; Fujimura M; Sakata H; Endo H; Tomata Y; Sato-Maeda M; Niizuma K; Tominaga T Neurol Res; 2019 Sep; 41(9):811-816. PubMed ID: 31064275 [No Abstract] [Full Text] [Related]
8. RNF213 as the major susceptibility gene for Chinese patients with moyamoya disease and its clinical relevance. Zhang Q; Liu Y; Zhang D; Wang R; Zhang Y; Wang S; Yu L; Lu C; Liu F; Zhou J; Zhang X; Zhao J J Neurosurg; 2017 Apr; 126(4):1106-1113. PubMed ID: 27128593 [TBL] [Abstract][Full Text] [Related]
9. Loss of mitochondrial ClpP, Lonp1, and Tfam triggers transcriptional induction of Rnf213, a susceptibility factor for moyamoya disease. Key J; Maletzko A; Kohli A; Gispert S; Torres-Odio S; Wittig I; Heidler J; Bárcena C; López-Otín C; Lei Y; West AP; Münch C; Auburger G Neurogenetics; 2020 Jul; 21(3):187-203. PubMed ID: 32342250 [TBL] [Abstract][Full Text] [Related]
10. Biochemical and Functional Characterization of RNF213 (Mysterin) R4810K, a Susceptibility Mutation of Moyamoya Disease, in Angiogenesis In Vitro and In Vivo. Kobayashi H; Matsuda Y; Hitomi T; Okuda H; Shioi H; Matsuda T; Imai H; Sone M; Taura D; Harada KH; Habu T; Takagi Y; Miyamoto S; Koizumi A J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26126547 [TBL] [Abstract][Full Text] [Related]
11. The emerging role of E3 ubiquitin ligase RNF213 as an antimicrobial host determinant. Zhang Y; Yuan Y; Jiang L; Liu Y; Zhang L Front Cell Infect Microbiol; 2023; 13():1205355. PubMed ID: 37655297 [TBL] [Abstract][Full Text] [Related]
13. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. Liu W; Morito D; Takashima S; Mineharu Y; Kobayashi H; Hitomi T; Hashikata H; Matsuura N; Yamazaki S; Toyoda A; Kikuta K; Takagi Y; Harada KH; Fujiyama A; Herzig R; Krischek B; Zou L; Kim JE; Kitakaze M; Miyamoto S; Nagata K; Hashimoto N; Koizumi A PLoS One; 2011; 6(7):e22542. PubMed ID: 21799892 [TBL] [Abstract][Full Text] [Related]
14. Molecular structure and function of mysterin/RNF213. Morito D J Biochem; 2024 Apr; 175(5):495-505. PubMed ID: 38378744 [TBL] [Abstract][Full Text] [Related]
15. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. Kamada F; Aoki Y; Narisawa A; Abe Y; Komatsuzaki S; Kikuchi A; Kanno J; Niihori T; Ono M; Ishii N; Owada Y; Fujimura M; Mashimo Y; Suzuki Y; Hata A; Tsuchiya S; Tominaga T; Matsubara Y; Kure S J Hum Genet; 2011 Jan; 56(1):34-40. PubMed ID: 21048783 [TBL] [Abstract][Full Text] [Related]
16. Temporal profile of the vascular anatomy evaluated by 9.4-tesla magnetic resonance angiography and histological analysis in mice with the R4859K mutation of RNF213, the susceptibility gene for moyamoya disease. Kanoke A; Fujimura M; Niizuma K; Ito A; Sakata H; Sato-Maeda M; Morita-Fujimura Y; Kure S; Tominaga T Brain Res; 2015 Oct; 1624():497-505. PubMed ID: 26315378 [TBL] [Abstract][Full Text] [Related]
17. RNF213 rare variants in an ethnically diverse population with Moyamoya disease. Cecchi AC; Guo D; Ren Z; Flynn K; Santos-Cortez RL; Leal SM; Wang GT; Regalado ES; Steinberg GK; Shendure J; Bamshad MJ; ; Grotta JC; Nickerson DA; Pannu H; Milewicz DM Stroke; 2014 Nov; 45(11):3200-7. PubMed ID: 25278557 [TBL] [Abstract][Full Text] [Related]
18. Importance of RNF213 polymorphism on clinical features and long-term outcome in moyamoya disease. Kim EH; Yum MS; Ra YS; Park JB; Ahn JS; Kim GH; Goo HW; Ko TS; Yoo HW J Neurosurg; 2016 May; 124(5):1221-7. PubMed ID: 26430847 [TBL] [Abstract][Full Text] [Related]
19. The Role of RNF213 4810G>A and 4950G>A Variants in Patients with Moyamoya Disease in Korea. Park YS; An HJ; Kim JO; Kim WS; Han IB; Kim OJ; Kim NK; Kim DS Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29160859 [TBL] [Abstract][Full Text] [Related]
20. Moyamoya Disease and Spectrums of RNF213 Vasculopathy. Bang OY; Chung JW; Kim DH; Won HH; Yeon JY; Ki CS; Shin HJ; Kim JS; Hong SC; Kim DK; Koizumi A Transl Stroke Res; 2020 Aug; 11(4):580-589. PubMed ID: 31650369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]